<DOC>
	<DOCNO>NCT02780349</DOCNO>
	<brief_summary>Demonstrate safety performance WIRION™ EPS subject undergo low extremity atherectomy treatment Peripheral Arterial Disease ( PAD )</brief_summary>
	<brief_title>Evaluation WIRION™ EPS Lower Extremities Arteries</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . Subject least 18 year age 2 . Subject authorized representative , sign write Informed Consent form participate study , prior study related procedure 3 . Subject willing comply protocol requirement return treatment center require clinical evaluation 4 . Rutherford classification 24 5 . Has moderate severe calcification visualize angiogram femoropopliteal artery 6 . Planned atherectomy native femoropopliteal artery 7 . Reference vessel diameter intend filter location must visually estimate ≥3.5mm ≤6.0mm 8 . An adequate `` land zone '' placement WIRION™ device distal target lesion least 30mm 9 . A female subject eligible child bear potential negative pregnancy test within previous 7 day agree remain birth control throughout study 1 . Any planned surgical endovascular intervention within 30 day index procedure 2 . A lesion deem accessible WIRION™ EPS 3 . Inability take aspirin ADP receptor antagonists 4 . History bleed diathesis coagulopathy refuse blood transfusion deem necessary 5 . Has perforation , dissection , injury access target vessel require additional stenting surgical intervention enrollment 6 . Subject enrol another drug device study protocol reach primary endpoint ( participate registry study exclude ) 7 . Life expectancy le 12 month 8 . Known severe renal insufficiency ( eGFR &lt; 30 ml/min/1.72m2 ) . 9 . ≤1vessel tibial runoff status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>